Genetic Links Uncovered
Recent groundbreaking research, involving the DNA analysis of nearly 28,000 individuals using popular weight loss medications, has revealed a crucial connection
between genetic makeup and drug efficacy. These drugs, which mimic natural hormones like GLP-1 and GIP to regulate appetite and metabolism, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), exhibit a wide range of patient outcomes. For instance, while some participants in a study lost over 25% of their body weight on semaglutide, others experienced virtually no change. The study, published in Nature, identified a specific gene variant that influences how well these drugs bind to their receptors. Individuals with one copy of this variant lost an average of 0.76 kg more over eight months, while those with two copies saw an additional 1.5 kg reduction. This genetic factor was also correlated with the intensity of nausea and vomiting, with tirzepatide showing a notable increase in vomiting incidents among certain individuals.
Indian Population Insights
Emerging evidence suggests that genetic factors play a considerable role in the varied weight loss responses observed within the Indian population. Experts in India have noted that previous studies on local populations have already demonstrated how variations in genes like FTO and VDR can significantly impact responses to dietary changes. Furthermore, research has indicated that certain genes, such as the Neurobeachin gene, may influence weight loss trajectories for individuals on GLP-1 based therapies. The latest international study strengthens this understanding with more robust data, making these findings particularly relevant for India, given the diverse range of obesity presentations and the increasing adoption of GLP-1 drugs. Future well-designed studies focusing on Indian populations are essential to ascertain if genetic profiling can truly personalize obesity treatment strategies and pinpoint individuals who are most likely to benefit from specific weight-loss therapies.
Pharmacogenomics Explained
The differential responses to weight loss drugs are a prime example of pharmacogenomics, the study of how an individual's genetic makeup influences their body's reaction to medications. In India, clinicians have observed distinct patient outcomes, categorizing responses into 'super', 'partial', and 'non-responders'. While some patients experience significant reductions in both weight and HbA1c (a measure of average blood sugar over three months), others might see only weight loss or only a dip in HbA1c. In a smaller group, neither parameter improves. The field of pharmacogenomics aims to leverage DNA analysis to help healthcare providers select the most effective medications and appropriate dosages, thereby maximizing benefits and minimizing adverse side effects. While the current research focuses on Caucasian populations, it opens the door for broader investigations into how ethnicity, gender, age, and specific diabetes subtypes, like Insulin Resistant Obese Diabetes (IROD), might influence drug efficacy, especially for South Asian populations.
